Trials / Completed
CompletedNCT04425746
Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium
A Phase II, Multicentre, Double-blind, Placebo Controlled, Pilot Study to Evaluate the Safety and Efficacy of CUV1647 (Afamelanotide) as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Clinuvel Pharmaceuticals Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the safety and efficacy of afamelanotide (previously developed as CUV1647) as adjunctive therapy in patients undergoing photodynamic therapy using porfimer sodium.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afamelanotide | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-08-05
- Primary completion
- 2009-05-28
- Completion
- 2009-05-28
- First posted
- 2020-06-11
- Last updated
- 2021-10-01
- Results posted
- 2021-10-01
Source: ClinicalTrials.gov record NCT04425746. Inclusion in this directory is not an endorsement.